Mosunetuzumab - Genentech

Drug Profile

Mosunetuzumab - Genentech

Alternative Names: Anti-CD20/CD3 monoclonal antibody; Anti-CD20/CD3 T-cell dependent bispecific antibody; BTCT 4465A; CD20-TBD; RG7828; RO7030816

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 25 Sep 2018 Roche initiates enrolment in a phase I trial for Non-Hodgkin's lymphoma (Combination therapy, Monotherapy, Second line therapy or greater) in USA (IV) (NCT03671018)
  • 24 Sep 2018 Hoffmann-La Roche plans a phase Ib/II trial for Non-Hodgkin lymphoma (Combination therapy) in USA (NCT03677141)
  • 19 Sep 2018 Hoffmann-La Roche plans a phase I/II trial for Diffuse large B-cell lymphoma in October 2018 (IV) (NCT03677154)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top